Company intelligence / Profile preview

amcure GmbH

Stutensee, Baden-Württemberg, Germany

Ownership: Private
Employees: ~4
Development stage: Other

Overview

amcure developed AMC303, an allosteric inhibitor of CD44v6 with significant efficacy in proof-of-concept animal studies against highly metastatic epithelial cancers. The company was liquidated in September 2024 due to lack of funding for further clinical studies.

Therapeutic areas: Oncology
Modalities: Small molecules (allosteric inhibitor)
Industry: Biotech

Drug pipeline

1 asset

amc303

Partnerships

No major pharmaceutical or biotech partnerships reported

Beyond the preview

Go deeper on amcure GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amcure GmbH.

Explore the full profile